[ Price : $8.95]
FDA cautions that noninvasive prenatal screening tests can give false results that can lead to inappropriate decisions without a c...[ Price : $8.95]
FDA reiterates concerns with phosphatidylinositol 3-kinase (PI3K) inhibitors and their approval for treating hematological maligna...[ Price : $8.95]
Federal Register notice: FDA permanently debars Yvelice Villaman-Bencosme from providing services in any capacity to a person that...[ Price : $8.95]
Federal Register notice: FDA is revoking the emergency use authorizations on five no-longer-marketed Covid-19 tests.[ Price : $8.95]
Writing in an online Lancet Oncology article, FDA officials outline challenges with current PI3K inhibitors that have the agency r...[ Price : $8.95]
A Hogan Lovells analysis of FDAs recent guidance on clinical trial diversity plans says such plans should be an important part of ...[ Price : $8.95]
Nektar Therapeutics and Bristol Myers Squibb end their clinical development program for bempegaldesleukin in combination with Opdi...[ Price : $8.95]
Due to overall survival concerns, TG Therapeutics withdraws its accelerated approval of Ukoniq (umbralisib), a PI3K inhibitor for ...